Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov56610.25208/vdv566ArticlesСтатьиReview ArticleUVA-1 therapy of localized scleroderma and other diseases accompanied by skin sclerosisУФА-1 терапия локализованной склеродермии и других заболеваний, сопровождающихся склерозом кожиVOLNUKHINV AВОЛНУХИНВ А

д.м.н., профессор, ведущий научный сотрудник

volnuhin@cnikvi.ruSAMSONOVV AСАМСОНОВВ А

д.м.н., профессор, главный научный сотрудник

State Research Center of Dermatovenereology and Cosmetology Ministry of Healthcare of the Russian FederationФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России15102013895NO5 (2013)№5 (2013)506811032020Copyright ©; 2013, VOLNUKHIN V.A., SAMSONOV V.A.Copyright ©; 2013, ВОЛНУХИН В.А., САМСОНОВ В.А.2013VOLNUKHIN V.A., SAMSONOV V.A.ВОЛНУХИН В.А., САМСОНОВ В.А.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/566

The study results confirm the efficacy of the UVA-1 therapy for patients with localized scleroderma, extragenital lichen sclerosus et atrophicus, sclerodermatous chronic graft-versus-host disease and scleredema adultorum. The therapy has an anti-inflammatory and anti^m^ action, arrests progression and reduces the activity of the disease process, and has a good efficacy and safety profile.

В обзоре проанализированы данные литературы по эффективности, механизмам действия и безопасности УФА-1 терапии локализованной склеродермии и других заболеваний, сопровождающихся склерозом кожи. Результаты проведенных исследований свидетельствуют об эффективности применения УФА-1 терапии у больных локализованной склеродермией, экстрагенитальным склероатрофическим лихеном, склеродермоподобной формой хронической реакции «трансплантат против хозяина», склередемой взрослых. Данный вид терапии оказывает противовоспалительное и антифиброзное действие, позволяет остановить прогрессирование и уменьшить активность патологического процесса, обладает хорошим профилем эффективности/безопасности.

UVA-1 therapyUVA-1 radiationsclerodermalichen sclerosus et atrophicuschronic graft-versus-host diseasescleredema adultorumУФА-1 терапияУФА-1 излучениесклеродермиясклероатрофический лихенхроническая реакция «трансплантат против хозяина»склередема взрослыхMutzhas M.F., Holzle E., Hofmann C. et al. A new apparatus with high radiation energy between 320 and 460 nm: physical description and dermatological applications. J Invest Dermatol 1981; 76: 42-47.Godar D.E. Preprogrammed and programmed cell death mechanisms of apoptosis: UV-induced immediate and delayed apoptosis. Photochem Photobiol 1996; 63(6): 825-30.Godar D.E. UVA1 radiation triggers two different final apoptotic pathways. J Invest Dermatol 1999; 112(1): 3-12.Kerr A.C., Ferguson J., Attili S.K. et al. Ultraviolet A1 phototherapy: a British Photodermatology Group workshop report. Clinical and Experimental Dermatology 2012; 37: 219-226.Tewari A., Sarkany R.P., Young A.R. UVA1 induces cyclobutane pyrimidine dimers but not 6-4 photoproducts in human skin in vivo. J Invest Dermatol 2012; 132(2): 394-400.Skov L., Hansen H., Allen M. et al. Contrasting effects of ultraviolet A1 and ultraviolet B exposure on the induction of tumour necrosis factor-а in human skin. Br J Dermatol 1998; 138(2): 216-220.McLoone P., Simics E., Barton A. et al. An action spectrum for the production of cis-urocanic acid in human skin in vivo. J Invest Dermatol 2005; 124(5): 1071-1074.Morita A., Werfel T., Stege H. et al. Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. J Exp Med 1997; 186(10): 1763-1768.Breuckmann F., Pieck C., Kreuter A. et al. Opposing effects of UVA1 phototherapy on the expression of bcl-2 and p53 in atopic dermatitis. Arch Dermatol Res 2001; 293(4): 178-183.Yamauchi R., Morita A., Yasuda Y. et al. Different susceptibility of malignant versus nonmalignant human T cells toward ultraviolet A-1 radiation-induced apoptosis. J Invest Dermatol 2004; 122(2): 477-483.Волнухин В.А., Мурадян Н.Л., Кату-нина О.Р. Особенности нарушений Т-клеточных иммунных процессов в коже больных ограниченной склеродермией и их динамика в процессе УФА-1 терапии. Вестн дерматол и венерол 2009; 6: 74-80Polderman M.C., van Kooten C., Smit N.P. et al. Ultraviolet-A (UVA-1) radiation suppresses immunoglobulin production of activated B lymphocytes in vitro. Clin Exp Immunol 2006; 145(3): 528-534.Grabbe J., Welker P., Humke S. et al. High-dose ultraviolet A1 (UVA1), but not UVA/UVB therapy, decreases IgE-binding cells in lesional skin of patients with atopic eczema. J Invest Dermatol 1996; 107(3): 419-422.Dumay O., Karam A., Vian L. et al. Ultraviolet AI exposure of human skin results in Langerhans cell depletion and reduction of epidermal antigen-presenting cell function: partial protection by a broad-spectrum sunscreen. Br J Dermatol 2001; 144(6): 1161-1168.Seite S., Zucchi H., Moyal D. et al. Alterations in human epidermal Langerhans cells by ultraviolet radiation: quantitative and morphological study. Br J Dermatol. 2003; 148(2): 291-299.Guhl S., Stefaniak R., Strathmann M. et al. Bivalent effect of UV light on human skin mast cells-low-level mediator release at baseline but potent suppression upon mast cell triggering. J Invest Dermatol 2005; 124(2): 453-456.Guhl S., Hartmann K., Tapkenhinrichs S. et al. Ultraviolet irradiation induces apoptosis in human immature, but not in skin mast cells. J Invest Dermatol 2003; 121(4):837-844.Kronauer C., Eberlein-Konig B., Ring J., Behrendt H. Influence of UVB, UVA and UVA1 irradiation on histamine release from human basophils and mast cells in vitro in the presence and absence of antioxidants. Photochem Photobiol 2003; 77(5): 531-534.Kreuter A., Hyun J., Skrygan M. et al. Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma. Br J Dermatol 2006; 155(3): 600-607.von Kobyletzki G., Pieck C., Hoxtermann S. et al. Circulating activation markers of severe atopic dermatitis following ultraviolet A1 cold light phototherapy: eosinophil cationic protein, soluble interleukin-2 receptor and soluble interleukin-4 receptor. Br J Dermatol 1999; 140(5): 966-968.Szegedi A., Simics E., Aleksza M. et al. Ultraviolet-A1 phototherapy modulates Th1/Th2 and Tc1/Tc2 balance in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44(7): 925-931.Smit N., Musson R., Romijn F. et al. Effects of ultraviolet A-1 radiation on calcineurin activity and cytokine production in (skin) cell cultures. Photochem Photobiol 2010; 86(2): 360-66.Musson R.E., Mullenders L.H., Smit N.P. Effects of arsenite and UVA-1 radiation on calcineurin signaling. Mutat Res 2012; 735(1-2): 32-38.Grewe M., Gyufko K., Krutmann J. Interleukin-10 production by cultured human keratinocytes: regulation by ultraviolet B and ultraviolet A1 radiation. J Invest Dermatol 1995; 104(1): 3-6.Krutmann J., Grewe M. Involvement of cytokines, DNA damage, and reactive oxygen intermediates in ultraviolet radiation-induced modulation of intercellular adhesion molecule-1 expression. J Invest Dermatol 1995; 105(1 Suppl): 67S-70S.Ju M., Chen K., Chang B., Gu H. UVA1 irradiation inhibits fibroblast proliferation and alleviates pathological changes of scleroderma in a mouse model. J Biomed Res 2012; 26(2): 135-142.Mempel M., Schmidt T., Boeck K. et al. Changes in collagen I and collagen III metabolism in patients with generalized atopic eczema undergoing medium-dose ultraviolet A1 phototherapy. Br J Dermatol 2000; 142: 3: 473-480.Yin L., Morita A., Tsuji T. The crucial role of TGF-p in the age-related alterations induced by ultraviolet A irradiation. J Invest Dermatol 2003; 120: 4: 703-705.Scharffetter K., Wlaschek M., Hogg A. et. al. UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res 1991; 283: 506-511.Petersen M.J., Hansen C., Craig S. Ultraviolet A irradiation stimulates collagenase production in cultured human fibroblasts. J Invest Dermatol 1992; 99(4): 440-444.Yin L., Yamauchi R., Tsuji T. et al. The expression of matrix metallopro-teinase-1 mRNA induced by ultraviolet A1 (340-400 nm) is phototherapy relevant to the glutathione (GSH) content in skin fibroblasts of systemic sclerosis. J Dermatol 2003; 30(3): 173-180.Herrmann G., Wlaschek M., Lange T.S. et al. UVA irradiation stimulates the synthesis of various matrix-metalloproteinases (MMPs) in cultured human fibroblasts. Exp Dermatol 1993; 2: 92-97.Wlaschek M., Bolsen K., Herrmann G. et al. UVA-induced autocrine stimulation of fibroblast-derived-collagenase by IL-6: a possible mechanism in dermal photodamage? J Invest Dermatol 1993; 101: 2: 164-168.Wlaschek M., Heinen G., Poswig A. et al. UVA-induced autocrine stimulation of fibroblast-derived collagenase/MMP-1 by interrelated loops of interleukin-1 and interleukin-6. Photochem Photobiol 1994; 59: 5: 550-556.Wlaschek M., Briviba K., Stricklin G.P. et al. Singlet oxygen may mediate the ultraviolet A-induced sinthesis of interstitial collagenase. J Invest Dermatol 1995; 104: 2: 194-198.Gruss C., Reed J.A., Altmeyer P. et al. Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts. Lancet 1997; 350: 1295-1296.Stege H., Berneburg M., Humke S. et al. High-dose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol 1997; 36: 6(Pt 1): 938-944.Gambichler T., Skrygan M., Tomi N.S. et al. Significant downregulation of transforming growth factor-p signal transducers in human skin following ultraviolet A1 irradiation. Br J Dermatol 2007; 156(5): 951-956.Kreuter A., Hyun J., Skrygan M. et al. Ultraviolet A1 phototherapy decreases inhibitory SMAD7 gene expression in localized scleroderma. Arch Dermatol Res 2006; 298(6): 265-272.Волнухин В.А., Мурадян Н.Л., Катунина О.Р. О роли профиброзных цитокинов в патогенезе локализованной склеродермии. Вестн дерматол и венерол 2012; 1: 28-33Sawada H., Isogai Z., Morita A. Altered decorin expression of systemic sclerosis by UVA1 (340-400 nm) phototherapy: immunohistochemical analysis of 3 cases. bMc Dermatol 2003; 12: 3: 2Gambichler T., Skrygan M., Tomi N.S. et al. Differential expression of decorin in localized scleroderma following Ultraviolet A1 irradiation. J Am Acad Dermatol 2007; 56(6): 956-959Trompezinski S., Pernet I., Mayoux C. et al. Transforming growth factor-p1 and ultraviolet A1 radiation increase production of vascular endothelial growth factor but not endothelin-1 in human dermal fibroblasts. Br J Dermatol 2000; 143(3): 539-545Breuckmann F., Stuecker M., Altmeyer P., Kreuter A. Modulation of endothelial dysfunction and apoptosis: UVAI-mediated skin improvement in systemic sclerosis. Arch Dermatol Res. 2004; 296(5): 235-239Chavan R., el-Azhary R. Cutaneous graft-versushost disease: rationales and treatment options. Dermatol Ther 2011; 24(2): 219-228.Kerscher M., Dirschka T., Volkenandt M. Treatment of localised scleroderma by UVA1 phototherapy. Lancet 1995; 346: 28: 1166.Camacho N.R., Sanchez J.E., Martin R.F. et al. Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells. J Am Acad Dermatol 2001; 45: 697-699.De Rie M.A., Enomoto D.N.H, Vries H.J.C., Bos J.D. Evaluation of medium-dose UVA1 phototherapy in localized scleroderma with the cutometer and fast fourier transform method. Dermatology 2003; 207: 298-301.Andres C., Kollmar A., Mempel M. et al. Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: a retrospective and prospective study. Br J Dermatol 2010; 162(2): 445-447.Su O., Onsun N., Onay H.K. et al. Effectiveness of medium-dose ultraviolet A1 phototherapy in localized scleroderma. Int J Dermatol 2011; 50(8): 1006-1013.Tuchinda C., Kerr H.A., Taylor C.R. et al. UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States. Photodermatol Photoimmunol Photomed 2006; 22(5): 247-253.Jacobe H.T., Cayce R., Nguyen J. UVA1 phototherapy is effective in darker skin: a review of 101 patients of Fitzpatrick skin types I-V. Br J Dermatol 2008; 159(3): 691-696.Pereira N., Santiago F., Oliveira H., Figueiredo A. Low-dose UVA1 phototherapy for scleroderma: what benefit can we expect? J Eur Acad Dermatol Venereol 2012; 26(5): 619-626.Kerscher M., Volkenandt M., Gruss C. et al. Low-dose UVA1 phototherapy for treatment of localized scleroderma. J Am Acad Dermatol 1998; 38: 1: 21-26.Gruss C.J., Kobyletzki G., Behrens-Williams S.C. et al. Effects of low dose Ultraviolet A-1 phototherapy on morphea. Photodermatol Photoimmunol Photomed 2001; 17: 149-155.Kreuter A., Gambichler T., Avermaete A. et al. Combined treatment of cal cipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea. Pediatr Dermatol 2001; 18: 3: 241-245.Gruss C., Stucker M., Kobyletzki G. et al. Low dose UVA1 phototherapy in disabling pansclerotic morphoea of childhood. Br J Dermatol 1997; 136(2): 293-294.Волнухин В.А., Мурадян Н.Л., Выборнова О.В. и др. УФА-1 терапия больных ограниченной склеродермией. Вестн дерматол и венерол 2007; 6: 4-8Бакулев А.Л., Платонова А.Н., Рассказов Я.А., Алипов Н.В. Клиническая эффективность применения УФА-1 терапии в комплексном лечении хронических дерматозов. Вестн дерматол и венерол 2012; 4: 64-69Kreuter A., Hyun J., Stucker M. et aal. A randomized controlled study of low-dose UVA1, mediumdose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 2006; 54(3): 440-447Sator P.G., Radakovic S., Schulmeister K. et al. Medium-dose is more effective than low-dose ultraviolet A1 phototherapy for localized scleroderma as shown by 20-MHz ultrasound assessment. J Am Acad Dermatol 2009; 60(5): 786-91Мурадян Н.Л. Сравнительная оценка эффективности УФА-1 и ПУВА-терапии при ограниченной склеродермии. Росс журн кожн и венерич болезней 2008; 6: 30-32Kreuter A., von Kobyletzki G., Happe M. et al. UVA1-Phototherapie bei Lichen sclerosus et atrophicus. Hautarzt 2001; 52: 878-881.Kreuter A., Gambichler T., Avermaete A. et al. Low-dose ultraviolet A1 pototherapy for extragenital lichen sclerosus: results of a preliminary study. J Am Acad Dermatol 2002; 46: 251-255.Rombold S., Lobisch K., Katzer K., et al. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Photodermatol Photoimmunol Photomed 2008; 24(1): 19-23.Beattie P.E., Dawe R.S., Ferguson J., Ibbotson S.H. UVA1 phototherapy for genital lichen sclerosus. Clin Exp Dermatol 2006; 31(3): 343-347.Steger J.W., Matthews J.H. UVA therapy for scleroderma. J Am Acad Dermatol 1999; 40(5 Pt 1): 787.Von Kobyletzki G., Uhle A., Pieck C. et al. Acrosclerosis in patients with systemic sclerosis responds to low-dose UV-A1 phototherapy. Arch Dermatol 2000; 136: 2: 275-276.Morita A., Kobayashi K., Isomura I. et al. Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol 2000; 43: 4: 670-674.Kreuter A., Breuckmann F., Uhle A. et al. Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis. J Am Acad Dermatol 2004; 50: 740-747.Rose R.F., Turner D., Goodfield M.J., Goulden V. Low-dose UVA1 phototherapy for proximal and acral scleroderma in systemic sclerosis. Photodermatol Photoimmunol Photomed 2009; 25(3): 153-155.Tewari A., Garibaldinos T., Lai-Cheong J. et al. Successful treatment of microstomia with UVA1 phototherapy in systemic sclerosis. Photodermatol Photoimmunol Photomed 2011; 27(2): 113-114.Durand F., Staumont D., Bonnevalle A. et al. Ultraviolet A1 phototherapy for treatment of acrosclerosis in systemic sclerosis: controlled study with half-side comparison analysis. Photodermatol Photoimmunol Photomed 2007; 23(6): 215-221.Grundmann-Kollmann M., Behrens S., Gruss C. et al. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol 2000; 42(1 Pt 1): 134-136.Stander H., Schiller M., Schwarz T. UVA1 therapy for sclerodermic graft-versus-host disease of the skin. J Am Acad Dermatol 2002; 46(5):799-800.Calzavara Pinton P., Porta F., Izzi T. et al. Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease. Haematologica 2003; 88(10): 1169-1175.Ziemer M., Thiele J.J., Gruhn B., Elsner P. Chronic cutaneous graft-versus-host disease in two children responds to UVA1 therapy: improvement of skin lesions, joint mobility, and quality of life. J Am Acad Dermatol 2004; 51(2): 318-319.Wetzig T., Sticherling M., Simon J.C. Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. Bone Marrow Transplant 2005; 35(5): 515-519.Fassihi H., Iqbal K., Garibaldinos T. et al. UVA1 phototherapy in the management of sclerodermatous Graft-Versus-Host Disease (GVHD): a report of two cases. Serbian Journal of Dermatology and Venereology 2009; 4: 147-152.Janiga J.J., Ward D.H., Lim H.W. UVA-1 as a treatment for scleredema. Photodermatol Photoimmunol Photomed 2004; 20: 210-211.Eberlein-Konig B., Vogel M., Katzer K. et al. Successful UVA1 phototherapy in a patient with scleredema adultorum. J Eur Acad Dermatol Venereol 2005; 19: 2: 203-204.Lewerenz V., Ruzicka T. Scleredema adultorum associated with type 2 diabetes mellitus: a report of three cases. J Eur Acad Dermatol Venereol 2007; 21: 4: 560-561.Kroft E.B.M., de Jong E.M.G.J. Scleredema diabeticorum case series: successful treatment with UV-A1. Arch Dermatol 2008; 144: 7: 947-948.Thumpimukvatana N., Wongpraparut C., Lim H.W. Scleredema diabeticorum successfully treated with ultraviolet A1 phototherapy. J Dermatol 2010; 37: 12: 1036-1039.Kochs C., Bockmann A., Hanneken S., Neumann N.J. Scleroedema diabeticorum. Erfolg-reiche Behandlung mit UV-A1-Phototherapie. Hautarzt 2011; 62: 4: 255-257.Asawanonda P., Khoo L.S.W., Fitzpatrick T.B., Taylor C.R. UV-A1 for keloid. Arch Dermatol 1999; 135: 348-349.Hannuksela-Svahn A., Grandal O.J., Thorstensen T., Christensen O.B. UVA1 for treatment of keloids. Acta Derm Venereol 1999; 79: 6: 490.Weber H.O., Schaller M., Metzler G. et al. Eosinophilic fasciitis and combined UVA1 - retinoid -corticosteroid treatment: two case reports. Acta Derm Venereol 2008; 88(3): 304-306.Silny W., Osmola-Mankowska A., Czarnecka-Operacz M. et al. Eosinophilic fascitis: a report of two cases treated with ultraviolet A1 phototherapy. Photodermatol Photoimmunol Photomed 2009; 25(6): 325-327.Schaller M., Romiti R., Wollenberg A. et al. Improvement of cutaneous manifestations in POEMS syndrome after UVA1 phototherapy. J Am Acad Dermatol 2001; 45(6): 969-970.Karamfilov T., Buslau M., Durr C., Weyers W. [Pansclerotic porphyria cutanea tarda after chronic exposure to organic solvents]. Hautarzt 2003; 54(5): 448-52.Kafi R., Fisher G.J., Quan T. et al. UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol 2004; 140(11): 1322-1324.Kreuter A., Gambichler T., Weiner S.M., Schieren G. Limited effects of UV-A1 phototherapy in 3 patients with nephrogenic systemic fibrosis. Arch Dermatol 2008; 144(11): 1527-1529.Tran K.T., Prather H.B., Cockerell C.J., Jacobe H. UV-A1 therapy for nephrogenic systemic fibrosis. Arch Dermatol 2009; 145(10): 1170-1174.Behrens S., Reuther T., von Kobyletzki G. et al. [Bleomycin-induced PSS-like pseudoscleroderma. Case report and review of the literature]. Hautarzt 1998; 49(9): 725-729.Breuckmann F., Freitag M., Rotterdam S. et al. Immunohistochemical investigations and introduction of new therapeutic strategies in scleromyxoedema: case report. BMC Dermatol 2004; 22; 4(1): 12.Kroft E.B.M., van de Kerkhof P.C.M., Gerritsen M.J.P., de Jong E.M.G.J. Period of remission after treatment with UVA-1 in sclerodermic skin diseases. J Eur Acad Dermatol Venereol. 2008; 22(7): 839-844.Sakakibara N., Sugano S., Morita A. Ultrastructural changes induced in cutaneous collagen by Ultraviolet A1 and psoralen plus ultraviolet A therapy in systemic sclerosis. J Dermatol 2008; 35(2): 63-69.Gambichler T., Terras S., Kreuter A. Treatment regimens, protocols, dosage, and indications for UVA1 phototherapy: Facts and controversies. Clin Dermatol 2013; 1(4): 438-454.Sterenborg H.J., van der Leun J.C. Tumorigenesis by a long wavelength UV-A source. Photochem Photobiol 1990; 51(3): 325-330.Runger T.M. Role of UVA in the pathogenesis of melanoma and non-melanoma skin cancer. A short review. Photodermatol Photoimmunol Photomed 1999; 15(6): 212-216.Ravnbak M.H., Wulf H.C. Pigmentation after single and multiple UV-exposures depending on UV-spectrum. Arch Dermatol Res 2007; 299(1): 25-32.Wang F., Garza L.A., Cho S. et al. Effect of increased pigmentation on the antifibrotic response of human skin to UV-A1 phototherapy. Arch Dermatol 2008; 144(7): 851-858.Dawe R.S. Ultraviolet A1 phototherapy. Br J Dermatol 2003; 148 (4): 626-637.Sacher C., Konig C., Scharffetter-Kochanek K. et al. Bullous pemphigoid in a patient treated with UVA-1 phototherapy for disseminated morphea. Dermatology 2001; 202(1): 54-57.Aljasser M.I., Lui H., Ball N.J., Kalia S. Persistent polymorphous light eruption after ultraviolet A1 phototherapy. Photodermatol Photoimmunol Photomed 2013; 29(1): 52-54.de Gruijl F.R. p53 mutations as a marker of skin cancer risk: comparison of UVA and UVB effects. Exp Dermatol 2002; 11 Suppl 1: 37-39.Beattie P.E., Finlan L.E., Kernohan N.M. et al. The effect of ultraviolet (UV) A1, UVB and solarsimulated radiation on p53 activation and p21. Br J Dermatol 2005; 152(5): 1001-1008.Wallenfang K., Stadler R. [Association between UVA1 and PUVA bath therapy and development of malignant melanoma]. Hautarzt 2001; 52(8): 705-707.Calzavara-Pinton P., Monari P., Manganoni A.M. et al. Merkel cell carcinoma arising in immuno-suppressed patients treated with high-dose ultraviolet A1 (320-400 nm) phototherapy: a report of two cases. Photodermatol Photoimmunol Photomed 2010; 26(5): 263-265.Kreuter A., Krieg T., Worm M. et al. Deutsche Dermatologische Gesellschaft. [AWMF Guideline no. 013/066. Diagnosis and therapy of circumscribed scleroderma]. J Dtsch Dermatol Ges 2009; 7 (Suppl 6): 1-14